-+ 0.00%
-+ 0.00%
-+ 0.00%

LANTERN PHARMA INC: CLINICAL TRIAL MET ALL PRIMARY ENDPOINTS FOR SAFETY, TOLERABILITY, AND ESTABLISHED A CLEAR RECOMMENDED PHASE 2 DOSE

Reuters·12/03/2025 13:36:17

Please log in to view news